Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial)
Brief Summary: Administration of steroid to the mother in imminent preterm delivery is a known effective practice to decrease the risk of respiratory distress syndrome and intraventricular haemorrhage in preterm infants if given with a week of the preterm delivery. This randomized clinical trial is performed to test the possibility whether the repeat dose of steroid results in further reduction of these diseases in case the mother is in imminent preterm delivery more than a week after the first antenatal steroid treatment.


Options:
A: Inclusion Criteria:

* Women who have previously received one completed course of ACS, at least 14 days ago and continue to be at increased risk of preterm birth
* Gestational age greater ≥ 26 weeks and gestational age \< 31 weeks

Exclusion Criteria:

* Women requiring chronic doses of corticosteroids secondary to medical conditions
* Women with a contraindication to corticosteroids
* Women with clinical evidence of chorioamnionitis (temperature ≥ 38°c)
* Known lethal congenital anomaly (e.g. anencephaly)
B: Inclusion Criteria:

* Greater than 14 days after first course of antenatal steroids;
* Less than 34 weeks of gestation;
* Identified by primary physician as continued risk for preterm delivery;
* Informed consent

Exclusion Criteria:

* Major congenital anomalies
* Multiple gestation of triplets or greater
* Mother with insulin dependent diabetes
C: Inclusion Criteria:

The pregnant women will be eligible for the trial entry if all following criteria are met:

* administration of a course of antenatal corticosteroid at least 7 days before the trial entry
* gestational age is less than 33.0 weeks 6 days\*
* very high risk of premature delivery\*\*
* none of the following therapies complications or therapies maternal long term systemic corticosteroid therapy severe clinical chorioamnionitis (maternal fever, increased CRP or another acute phase protein, uterine tenderness) lethal disease of the fetus
* informed consent obtained
* premature rupture of membranes is not contraindication for the trial entry

  \*Gestational age will be calculated from the mother's last menstrual period and confirmed by ultrasound before 20 weeks' gestation. In case the discrepancy in the estimates exceeds two weeks, ultrasound date is accepted.

  \*\*Very high risk of premature delivery is described as follows:
* elective delivery within within 4-48 hours, as indicated by the obstetrician on the basis of the clinical status of the mother and/or the fetus
* very high risk of spontaneous delivery within 4-48 hours, i.e.
* cervix is open \> 3 cm
* contractions of the uterus at 5-10 min intervals
* rupture of the membranes after the first course of ANC
* fetal and/or maternal indication for elective premature delivery or cesarean section
D: Inclusion criteria:

* Pregnant
* Gestational age \> 23.0 wks and \< 31.6 wks
* Singleton or twin pregnancy
* Intact membranes
* At-risk for spontaneous preterm delivery
* Received full course of corticosteroids within the previous 7 days

Exclusion criteria:

* Diagnosis of fetal lung maturity
* Chorioamnionitis
* Non-reassuring fetal testing
* Known major fetal anomaly
* Corticosteroid therapy, other than qualifying course
* Insulin dependent diabetes
* Active preterm labor at the time of randomization
* Delivery intended outside center
* Participation in any intervention study which influences neonatal morbidity or mortality
* Previous participation in this trial

Answer: C